[{"address1": "2 Holzman Street", "address2": "Science Park PO Box 4081", "city": "Rehovot", "zip": "7670402", "country": "Israel", "phone": "972 8 940 6472", "fax": "972 8 940 6473", "website": "https://www.kamada.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.", "fullTimeEmployees": 378, "maxAge": 86400, "priceHint": 4, "previousClose": 4.9, "open": 4.86, "dayLow": 4.74, "dayHigh": 4.86, "regularMarketPreviousClose": 4.9, "regularMarketOpen": 4.86, "regularMarketDayLow": 4.74, "regularMarketDayHigh": 4.86, "beta": 0.227, "trailingPE": 20.78261, "forwardPE": 15.933333, "volume": 22492, "regularMarketVolume": 22492, "averageVolume": 17667, "averageVolume10days": 13770, "averageDailyVolume10Day": 13770, "marketCap": 286799520, "fiftyTwoWeekLow": 4.08, "fiftyTwoWeekHigh": 6.53, "priceToSalesTrailing12Months": 1.9178143, "fiftyDayAverage": 5.2722, "twoHundredDayAverage": 5.39855, "currency": "USD", "enterpriseValue": 243168496, "profitMargins": 0.08331, "floatShares": 8956255, "sharesOutstanding": 57479500, "sharesShort": 33714, "sharesShortPriorMonth": 36847, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.00059999997, "heldPercentInsiders": 0.07315, "heldPercentInstitutions": 0.4921, "shortRatio": 1.65, "shortPercentOfFloat": 0.0011, "impliedSharesOutstanding": 59999900, "bookValue": 4.169, "priceToBook": 1.1465579, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": 12458000, "trailingEps": 0.23, "forwardEps": 0.3, "pegRatio": 3.15, "enterpriseToRevenue": 1.626, "enterpriseToEbitda": 9.574, "52WeekChange": -0.13562387, "SandP52WeekChange": 0.26238096, "lastDividendValue": 0.006, "lastDividendDate": 1371081600, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "KMDA", "underlyingSymbol": "KMDA", "shortName": "Kamada Ltd.", "longName": "Kamada Ltd.", "firstTradeDateEpochUtc": 1370007000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a88fd904-380d-3754-b686-3fbaf4e080d7", "messageBoardId": "finmb_9002466", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.78, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 48194000, "totalCashPerShare": 0.815, "ebitda": 25398000, "totalDebt": 8745000, "quickRatio": 1.976, "currentRatio": 4.245, "totalRevenue": 149544992, "debtToEquity": 3.548, "revenuePerShare": 2.859, "returnOnAssets": 0.02616, "returnOnEquity": 0.058969997, "freeCashflow": -17656250, "operatingCashflow": 8186000, "revenueGrowth": 0.229, "grossMargins": 0.40390998, "ebitdaMargins": 0.16984, "operatingMargins": 0.107030004, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]